Please assess the completion status of the following clinical trial:

Trial Title: Cytisine Versus Varenicline for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* daily tobacco smokers~* self-identify as Māori (indigenous New Zealander) or whānau (family) of Māori~* want to stop smoking in the next two weeks~* are at least 18 years of age~* are able to provide verbal consent~* reside in the Lakes District Health Board, Eastern Bay of Plenty or Tokoroa region at the time of enrolment~* have daily access to a mobile phone with text capability and/or email and access to the internet via computer or smartphone~* are eligible for subsidised varenicline under special authority conditions~Exclusion Criteria:~* are pregnant or breastfeeding~* are current users of other smoking cessation therapies (e.g. nicotine replacement therapy \[NRT\], buproprion \[Zyban\], clonidine, nortriptyline, e-cigarettes)~* are enrolled in another smoking cessation programme or another smoking cessation study~* have a contraindication for cytisine or varenicline~* have used varenicline or cytisine in the past 12 months~* have another person in their household involved in the trial~* have moderate or severe renal impairment,~* are being treated for active or latent TB~* have been treated for a heart attack, stroke, or severe angina within the last two weeks~* have uncontrolled high blood pressure (\> 150 mmHg systolic, \> 100 mmHg diastolic)~* have a history of seizures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cytisine plus behavioural support (Type: EXPERIMENTAL): 12-week course of cytisine capsules (1.5mg), with a decreasing dosing regimen (9mg/day for days 1-3, 7.5mg/day for days 4-12, 6mg/day for days 13-16, 4.5mg/day for days 17-20, 3.0mg/day from days 21-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription).
- Varenicline plus behavioural support (Type: ACTIVE_COMPARATOR): 12-week course of Varenicline tablets (0.5mg/1mg), with an increasing dosing regimen (0.5mg/day for days 1-3, 1.0mg/day for days 4-7, 2.0mg/day for day 8-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also receive withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription).

Based on this trial design, predict the completion outcome and termination type (if applicable).